Novo Nordisk: “It’s not a weight disease and diabetes”

The Danish Biopharma Company is swimming in the succession well. The basis for this is a single active ingredient: Semaglutide. This type of GLP-1 preparation is used under the trade name, Ozempic or Rybels is straight out of the Regalen geris. If diabetes medication is used, the research can lead to another positive effect.

How Bloomberg I have received a message that we have been included in the “SELECT Study”, while the pandemic status, deaths and illnesses due to Covid occur. If it is another article for the many blockbuster drugs, the weight problem is bigger, so the aftercare agent, that is a publication in the Journal of the American College of Cardiology.

Die Studie “Unterstreicht de Zusammenhang Zischen Fettleibigkeit und der Schwere der Covid-Erkrankung“, with Barry Popkin, Professor for Ernährungswissenschaften at the Gillings School of Global Public Health of the University of North Carolina is located. “We will not delete it, but with the reduction Lungenkapazität von Menschen with overweight or with other mechanisms, who a reduced Entzündung, zeeammenhängt”, so the Ernährungwissenschaftler, the wiederum not and the Study guarantees war.

“There is no such thing as a weight disease and diabetes,” Bloomberg as Professor Donna Ryan, the new borrower of the new SELECT study and as a reviewer for other pharmaceutical companies. The effect of the drugs is “much longer”.